JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

An immunoinformatics approach for a potential NY-ESO-1 and WT1 based multi-epitope vaccine designing against triple-negative breast cancer

  • 0Department of Biochemistry and Molecular Biology, University of Rajshahi, Rajshahi, 6205, Bangladesh.
Heliyon +

|

September 17, 2024

|

September 17, 2024

View abstract on PubMed

Summary

This summary is machine-generated.

This study designed a novel multiepitope vaccine targeting WT1 and NY-ESO-1 antigens for triple-negative breast cancer (TNBC). Immunoinformatics analysis suggests this vaccine can induce strong immune responses, offering a promising new therapeutic strategy for TNBC.

Area Of Science

  • Oncology
  • Immunology
  • Bioinformatics

Background

  • Breast cancer is a leading malignancy in women, with triple-negative breast cancer (TNBC) posing a significant therapeutic challenge due to its aggressive nature and lack of targeted receptors.
  • Current treatments for TNBC have limitations, necessitating the development of innovative therapeutic strategies like cancer vaccines.

Purpose Of The Study

  • To design a novel multiepitope vaccine utilizing WT1 and NY-ESO-1 antigenic proteins for the immunotherapy of triple-negative breast cancer (TNBC).

Main Methods

  • Identification and immunogenicity assessment of WT1 and NY-ESO-1 epitopes.
  • Construction of a multiepitope vaccine incorporating epitopes, linkers (GPGPG, AAY, EAAAK), and the 50S ribosomal L7/L12 protein adjuvant.
  • 3D modeling, molecular docking, and dynamic simulations to validate vaccine structure and stability.
  • Cloning of the vaccine construct into the pET28 (+) vector and in silico immunoinformatics analysis.

Main Results

  • The designed vaccine construct demonstrated high immunogenicity potential through epitope prediction and selection.
  • Structural analysis confirmed the stability and integrity of the vaccine-adjuvant complex.
  • In silico analysis indicated the vaccine's capacity to elicit robust humoral and cellular immune responses.

Conclusions

  • The computationally designed multiepitope vaccine holds significant promise as a potential therapeutic agent against triple-negative breast cancer (TNBC).
  • Further research and experimental validation are warranted to translate this immunoinformatic-driven approach into clinical application for TNBC treatment.

Keywords: